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Abstract: Transforming growth factor-beta (TGFβ1) is considered as a master regulator for many
intracellular signaling pathways, including proliferation, differentiation and death, both in health and
disease. It further represents an oncogenic factor in advanced tumors allowing cancer cells to be more
invasive and prone to move into the metastatic process. This finding has received great attention for
discovering new therapeutic molecules against the TGFβ1 pathway. Among many TGFβ1 inhibitors,
peptides (P17 and P144) were designed to block the TGFβ1 pathway. However, their therapeutic
applications have limited use, due to lack of selection for their targets and their possible recognition
by the immune system and further due to their potential cytotoxicity on healthy cells. Besides that,
P144 is a highly hydrophobic molecule with less dissolution even in organic solution. Here, we aimed
to overcome the dissolution of P144, as well as design nano-delivery strategies to protect normal cells,
to increase cellular penetration and to raise the targeted therapy of both P17 and P144. Peptides were
encapsulated in moieties of polymer hybrid protein. Their assembly was investigated by TEM,
microplate spectrum analysis and fluorescence microscopy. SMAD phosphorylation was analyzed by
Western blot as a hallmark of their biological efficiency. The results showed that the encapsulation of
P17 and P144 might improve their potential therapeutic applications.
Keywords: transforming growth factors; proliferation; polymer hybrid protein
1. Introduction
Transforming growth factor (TGFβ) is a secreted cytokine, having the ability to regulate and
control cell proliferation, migration, differentiation and cytoskeleton morphology [1–3]. Apart from
this fact, the role of TGFβ in controlling inflammation, wound healing and tissue repair received a lot of
interest [4]. However, its function as a tumor promoter at the end stage of cancer development resulted
in an impact issue, since it supports cancer growth, activates tumor angiogenesis and inhibits immune
responses [5–7]. Among many molecules that were used to inhibit TGFβ signaling pathway, TGFβ
inhibitory peptides have obtained great interest due to their efficient role in blocking of TGFβ signaling
pathways [8]. Peptide P144, TSLDASIIWAMMQN, is a very hydrophobic peptide obtained from the
membrane-proximal ligand-binding domain of b-glycan [9]. This peptide is designed to block TGFβR
III extracellular domains preventing cellular interaction between TGF ligand and its receptors [10].
Another soluble peptide is called P17, (KRIWFIPRSSWYERA) [11]. It was produced from a phage
library [12]. P17 can block TGF-β1, TGFβ2 and TGFβ3 with relative affinity binding reached 100%,
80% and 30% respectively [13]. The active inhibitory effect of both peptides was characterized in vivo
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and in vitro for several models of fibrosis and scleroderma [14]. Results have proven the potential
therapeutic value for both peptides to block the TGFβ pathway and to prevent the accumulation
of collagen fibers [15]. However, there is an urgent needing strategy to improve their dissolution,
prevent their aggregation and facilitate their delivery into animal models. P144 was used previously
either after it is suspended inside dimethyl sulfoxide (DMSO)-saline [16] or, after its integration into
the composition of the lipogel in the presence of 5% DMSO [17]. Both strategies were restricted due
to the presence of DMSO [18]. Additionally, both peptides can be distributed into the whole body,
with no specific delivery into a certain region. Leading to increase their accumulation inside healthy
tissues. Additionally, due to their amino acid structure, they can be recognized in the bloodstream and
then can be engulfed by the immune system or can be degraded inside the stomach by a biological
enzyme [19]. In the current study, the sonicated P144 and suspended P17 were internalized into the
bovine serum albumin matrix through amino–carboxyl interaction. Such attachment is characterized
by strong interaction between peptide and protein due to the presence of carboxyl, amino-groups and
hydrogen intermolecular interactions.
Additionally, the surface of the protein–peptide complex was further functionalized by
folic-acid-attached carboxymethyl cellulose (CMC; Supplementary Scheme S1A). Folic acid is used
as a ligand and can bind folate receptors. Additionally, CMC has mucoadhesive properties and
allows protein–peptide formulation to adhere and penetrate mucus layers. This strategy provides a
novel and concrete reason to strengthen the potential application of peptides as a targeted delivery.
The efficiency of encapsulated peptides (P144 and P17) and the pure peptides (with no addition of
DMSO or integration into lipogel) were studied by using two different hepatocellular carcinomas (HCC)
cell lines: hepatitis B-positive SNU449 cells, [20], that were characterized by a mesenchymal phenotype
expression [21] and the human epithelial HCC Hep3B cells [22] with different genetic characterization.
2. Materials and Methods
2.1. Chemicals
The suppliers of the chemicals were as follows. Carboxy methylcellulose (CMC) was purchased
from Fluka, Sigma-Aldrich (St. Louis, MO, USA), phosphate-buffered saline (PBS) tablets of pH 7.3
were purchased from Oxoid Limited Basingstoke (Hampshire, England); ethanol from Baker Analyzed,
Fisher Scientific, (Landsmeer, The Netherlands); bovine serum albumin (BSA), folic acid (FA), crystal
violet, 40,6-diamidino-2-phenylindole dihydrochloride (DAPI), paraformaldehyde, N-ethyl-N0- (3
dimethylaminopropyl)carbodiimide hydrochloride (EDAC), N-hydroxy succinimide (NHS), dimethyl
sulfoxide (DMSO) from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Fabrication of Protein–Peptide Mucoadhesive Carriers
A 1 mg amount of sonicated P144 and suspended P17 was mixed into BSA solution (50 µg/50 mL).
Then, the mixture will be grafted by carboxymethyl cellulose inside sterilized glass vials for 30 min
under rotation by a magnetic stirrer in the presence of EDAC/NHS. The complex was further coated by
5 mL of 50 µg/50 mL protamine and the stirrer was continued into addition for 10 min. Afterward, the
mixture was furthermore covered by folic-acid-attached carboxymethyl cellulose and the rotation was
completed in an additional 15 min. Un-reacted materials were removed by using a dialysis bag against
distilled water for 48 h. The water was changed several times. Then, the final product was lyophilized
at a freeze-drying machine while the material was kept at −20 ◦C until use.
2.3. Characterization of the Protein-Peptides Mucoadhesive Formulation
2.3.1. Transmission Electron Microscopy (TEM)
A 10 µL volume of nanoparticle suspension was deposited on the copper grid and air-dried
before measurement. Copper grids sputtered with carbon films were used to support the sample.
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High-resolution TEM images of nanoparticles were analyzed by a Hitachi HT 7700 operating (Hitachi,
Japan) at 100 kV, coupled with a GATAN camera ORIUS SC600 (Gatan, Inc., Pleasanton, CA, USA))
with a resolution of 7 megapixels. The GATAN camera is controlled by Digital Micrograph (Gatan,
Inc., Pleasanton, CA, USA) [23]
2.3.2. UV–Vis Spectroscopy
The absorbance of folic acid and rhodamine was measured by using a multiplate reader at the
option of UV Absorbance Spectrophotometer in multiplate wells. A 500 µL mL volume of fabricated
nanoparticles was scanned at a range of 300–600 nm [24].
2.3.3. Zeta Potential
The electrophoretic mobility of samples was determined by photon correlation spectroscopy by
using a Zeta Nano Sizer (Malvern Instruments, Malvern, UK). All measurements were performed at 25
◦C. Five following measurements were taken for analysis; each was run five times with a delay of 5 s
after each measurement [25].
2.3.4. ImageJ Analysis and Calculation of the Surface Roughness
The measurements for the light microscopic images (400 µm) were carried out in pixels. Thus,
setting up a scale bar for calibration for the calculation of the actual area was not required. Since, in
the “Image” option of ImageJ, under Adjust, “size” was selected. Then, the pixel of width and length
was adjusted and it is followed by using the “Surface Plot” option in “Analyze”. This led to the area
measurement of the complete image in pixels.
The measured peaks upon the material surface expressed the status of material that was either
roughness or granules, while no peaks were measured in the case of soft materials or those that did not
contain any granulated materials [26].
2.4. Cell Culture
Hep3B and SNU449 cells were obtained from the European Collection of Cell Cultures (ECACC).
Cell lines were never used in the laboratory for longer than 4 months after receipt or resuscitation. All
cells were maintained in DMEM media (Lonza, Basel, Switzerland) supplemented with 10% FBS (Sera
Laboratories International Ltd., West Sussex, UK), penicillin (100 U/mL), streptomycin (100 µg/mL),
amphotericin (2.5 µg/mL) and L-glutamine (2 mM). They were maintained in a humidified atmosphere
at 37 ◦C and 5% CO2. Cells were observed under an Olympus IX-70 microscope.
2.4.1. Cellular Uptake
Ten thousand human liver cancer cell lines were seeded upon the surface of a sterilized cover slip
that was laid in the bottom of 6 multi-well microplates. After 24 h from their growth, encapsulated
peptides and non-encapsulated (50 µg/mL) were added to each well and incubated in a humidified
atmosphere of 37 ◦C, 5% CO2. SNU449 and Hep3B cell lines were fixed by 4% paraformaldehyde then
washed by PBS (phosphate-buffered saline) at pH 7.2. Cells were then stained by DAPI (nuclear stain)
for 30 min and washed twice by PBS,7.2. Cellular uptake was analyzed after 24 h by red (TRITC),
green (FITC) and blue (DAPI) channels of fluorescence microscopy. After that, images were captured
by fluorescence microscopy with a digital camera [27,28].
2.4.2. Proliferation Assay
To evaluate cell proliferation, crystal violet assay was performed at 3, 6, 12, 24, 48 and 72 h [29].
Briefly, 7 × 103 cells/well were seeded in 96-well flat-bottom plates and allowed to grow for 24 h.
Encapsulated peptides (P17 and P144) and free capsules were then added at different concentrations
(10, 50, 100, 200 µg/mL). After incubation for a certain time, DMEM media was removed and cells were
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washed using PBS 3 times. Cells were then fixed for 10 min in a solution of buffered formalin (3.7%),
and then cells were washed with PBS (pH 7.3) and subsequently stained with a 0.01% crystal violet
solution. After removing excess stain, the crystal violet stained cells were dissolved in 1 mL of a 10%
sodium dodecyl sulfate solution for 2 h under orbital shaking and the optical density of the extracted
dye was read with a spectrophotometer at 590 nm. Optical density measurements give an indication of
the relative number of viable cells present at the time of adding dye and this is used to create survival
curves. Cell survival at each dose point was expressed as a percentage of the control survival rate.
2.4.3. Western Blot Analysis
Total protein extracts were obtained as described previously [30], separated by SDS/PAGE (12%
polyacrylamide gels) and transferred on to PVDF membranes. After blocking with 5% (w/v) non-fat
milk TBST (Tris-buffered saline solution containing 0.05% (v/v) Tween 20), the membranes were
incubated overnight with the corresponding antibody in a 0.5% non-fat milk TBST (diluted 1:5000 for
β-actin and 1:1000 for all others). After washing and incubating the membrane with an appropriate
peroxidase-conjugated antibody (diluted 1:5000) for 1 h at 21 ◦C, antibody binding was revealed using
ECL® (GE-Healthcare). β-actin was used as a loading control.
2.5. Ethical Approval
All experiments were conducted in accordance with US National Institutes of Health Guidelines
for the Care and Use of Laboratory Animals and cell line experiments Guide for the Care and Use
of Laboratory Animals after being approved by the relevant Ethical Committee and authorized by
the Italian and German Ministry of Health. This study was also approved by the Research Ethics
Committee of Kafrelsheikh University.
3. Results
3.1. Physical Properties of Peptide P17 and P144
P144 is a very hydrophobic peptide, has a limited dissolution either inside aqueous solution or
even in an organic solvent such as DMSO (Figure 1A,B) [10]. This drawback leads to a reduction of its
delivery into preclinical studies and minimizes its potential applications. The dissolution of bulk P144
was obtained by using physical sonication for 15 min under high amplitude to prevent microscopic
bubbles in solution. After sonication, the bulk of P144 was separated into a colloidal suspension
containing small peptide particles (Figure 1C,D). However, these small particles turned into aggregation
after their precipitation (Figure 1G). The bulk of P144 is formed by tiny small molecules held together
by electrostatic force. These small particles had lost their ionic balance after their separation. For this
reason, the separated particles of P144 tend to bind back forming an aggregated state. Contrarily, P17
is very soluble in water, forming a colloidal suspension with good stability [11]. Meanwhile, P17 has a
widescreen attachment with three TGFβ isoforms such as TGFβ1, TGFβ2 and TGFβ3.
To investigate their properties with fluorophore conjugation and to follow their cellular uptake,
the anti-TGFβ inhibitory peptides (P17 and P144) were labeled by rhodamine (RG6; Figure 1G) [31].
Rhodamine-labeled peptides showed strong absorbance at 550 nm associated with a peak of pure
rhodamine [32]. Their interaction is attributed to the amino group of rhodamine and the carboxyl
group of peptides. It is noticed that rhodamine-doped peptides have a strengthened second peak
localized at 490 nm. This peak emitted green fluorescence with fluorescence microscopy (Figure 1G,H).
In addition, sonicated P144 and dissolved P17 were shown as aggregated peptides even after their
cellular uptake (Figure 1H).
Pharmaceutics 2020, 12, 421 5 of 18
Pharmaceutics 2020, 12, x 5 of 18 
1H). In addition, sonicated P144 and dissolved P17 were shown as aggregated peptides even after 
their cellular uptake (Figure 1H). 
 
Figure 1. Optical microscopic image of P144 dissolution. (A) P144 dissolved by DMSO; (B) ImageJ 
analysis of P144 dissolved by DMSO; (C) P144 dissolved by sonication; (D) ImageJ analysis of 
sonicated P144; (E) rhodamine-labeled peptide P144; (F) rhodamine-labeled peptide P17; (G) 
fluorescence microscopy for images labeled P144. (H; a–d) Cellular uptake of sonicated P144; (E–H) 
Cellular uptake of suspended P17. 
3.2. Fabrication of Protein–Peptide Mucoadhesive Complex  
Both peptides (P17 and 144) were suspended in PBS at pH 7.2 and then P144 was sonicated by 
ultrasonicator. The processing time was adjusted for 15 min under amplitude five (intensity). The 
processing time is further divided into three steps each one has taken 5 min. Under magnetic stirrer, 
the sonicated P144 and suspended P17 were then integrated into BSA moieties in the presence of 
carbodiimide and n-hydroxy succinimide [33]. The reaction was continued by completing the stirrer 
for 15 min and then carboxymethyl cellulose was added and the stirring was further continued into 
addition for 10 min. Free capsules (with no encapsulated peptides) were labeled by fluorescence 
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Figure 1. Optical microscopic image of P144 dissolution. (A) P144 dissolved by DMSO; (B) ImageJ
analysis of P144 dissolved by DMSO; (C) P144 dissolved by sonication; (D) ImageJ analysis of sonicated
P144; (E) rhodamine-labeled peptide P144; (F) rhodamine-labeled peptide P17; (G) fluorescence
microscopy for images labeled P144. (H; a–d) Cellular uptake of sonicated P144; (E–H) Cellular uptake
of suspended P17.
3.2. Fabrication of Protein–Peptide ucoadhesive o plex
Both peptides (P17 and 144) ere suspended in PBS at pH 7.2 and then P144 was sonicated
by ultrasonicator. The processing time was adjusted for 15 min under amplitude five (intensity).
The processing time is further divided into three steps each one has taken 5 min. Under magnetic
stirrer, the sonicated P144 and suspended P17 were then integrated into BSA moieties in the presence
of carbodiimide and n-hydroxy succinimide [33]. The reaction was continued by completing the stirrer
for 15 min and then carboxymethyl cellulose was added and the stirring was further continued into
addition for 10 min. Free capsules (with no encapsulated peptides) were labeled by fluorescence
isothiocyanate (Figure 5 and Supplementary Scheme S1B). Both formulations were then functionalized
by adding protamine to observe helix structure [34]. Indeed, protamine can modify the size of particles
without any restriction for moieties of the protein–peptide complex. These results showed good
turbidity after using protamine due to the presence of arginine (Figure 2A,B) [34]. Peptide protein
mucoadhesive nanoparticles exhibit unaggregated and rounded core-shell assembly (Figure 2C–E) and
have Z-potential value (−25 mV; Figure 3). This indicates good physical stability of nanosuspensions
due to electrostatic repulsion of indivi ual particle . Additionally, folic acid doped carboxym thyl
cellulose was added as the last layer to the formulation. This may strengthen the properties of
mucoadhesive targeting therapy (Figure 2F,G and Supplementary Scheme S1A). Indeed, this strategy
was designed by using two layers from CMC, one is integrated into the middle layer and the second is
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added as the last layer. Therefore, this mechanism allows facilitating cellular adhesion and penetration,
leading to increased stability of peptides in aqueous solution and improved cellular uptake for both
peptides (P144 and P17; Supplementary Scheme S2).
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Figure 3. Zeta potential measurement after five successful running data. Each one was run five times
with a delay of 5 s after each measurement.
3.3. Biological Experiments: Cellular Uptake
The rhodamine-labeled non-encapsulated peptides were accumulated successfully inside the
cytoplasm as shown by fluorescent emission of TRITC channel (red spots). On the other hand, the green
color was shown by using the FITC channel, indicating that peptides are able to emit green intensity
after their doping with R6G (Figure 1G,H). Similarly, encapsulated peptides that were labeled by
rhodamine showed good intensity for both TRITC and FITC channels after their cellular internalization
as well (Figure 4A−P). Indeed, the labeled peptides were accumulated around the perinuclear region
of both Hep3B and SNU449 cell lines. Such emissions are mostly related to the presence of tryptophan,
tyrosine and phenylalanine. While in the presence of rhodamine, the fluorescent signal is strengthened
and intensity is increased. It is reported that tryptophan is highly sensitive to hydrogen bonding and
non-covalent interactions, displaying a red, green and blue shift [35]. Additionally, its indole group is
considered the dominant source of UV absorbance at ∼280 nm and emission at ∼350 nm [36].
The results indicate that there is a good distribution of adsorbed peptides inside cytoplasm
after their encapsulation compared to those used with no encapsulation. Similarly, free capsules
were localized inside cytoplasm after their cellular adsorption (Figure 5). On the contrary,
the non-encapsulated peptides accumulated in an aggregated state even after their cellular uptake
(Figure 1H (merged)). This perhaps explains that the separation of P144 bulk into small particles by
using physical sonication is not really enough to keep these particles separately because these particles
tend to bind back after their accumulation.
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Figure 5. Fluorescence i ages of cellular uptake. S U449-adsorbed free capsules.
3.4. Deter ination of uclear orphology by sing I tai i g
I (4′, 6-dia idino-2-phenylindole) is a specific fluorophore for a nucleic acid because it is
a le t i refere tially to adenine thymine base pair and also to phosphate groups of DNA [37–40].
This mechanism allows researchers to discover the alteration associated with nuclear morphology. In
the current study, DAPI staining indicates that there are no changes in nuclear morphology for cells
SNU449 after their exposure to 50 µg/mL free capsules (empty vehicles) with no encapsulated peptides
f r 24 h (Figure 6). However, there are clear alterations for nuclear morphology in both cell lines
Hep3B and SNU449 after their exposure to encapsulated P17 and P144 for 24 h. Results showed that
there was an increasing number of condensed uclei, nuclear fragmentation and hypotrophy [41–43].
Addition lly, their morpholog suffered from phenot pe alteration (Figure 7, Part 1 and Part 2).
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Figure 7. (Part 1) SNU449 and Hep3B cell lines suffered from phenotype changes. (A) control SNU449.
(B) SNU449 exposed to 50 µg/ L EP144. (C)SNU449 exposed to 50 µg/ L EP17. (D) control Hep3B.
(E) ep3B exposed to 50 µg/ L EP144. (F) ep3B exposed to 50 µg/ L EP17. (Part 2) Fluorescence
i ages of orphology of PI staining ( ) uclear degradation at ep3B. (B) uclear condensation
at ep3B. ( ) uclear frag entation at S 449. ( ) uclear activation at S 449.
On the contrary, the Hep3B and SNU449 exposed to non-encapsulated peptides exhibited no
more changes in their morphology. However, a slightly condensed nucleation was shown (Figure 8,
Part 1 and Part 2). Additionally, quantitative analysis of nuclear morphology indicates that Hep3B
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Figure 8. (Part 1) Optical microscopy images SNU449 and Hep3B cell lines suffered from phenotype
changes. (A) control SNU449. (B) SNU449 exposed to 50 µg/mL P144. (C) SNU449 exposed to
50 µg/mL P17. (D) control Hep3B. (E) Hep3B exposed to 50 µg/mL P144. (F) Hep3B exposed to
50 µg/mL P17. (Part 2) Fluorescence images of the morphology of DAPI staining; (A) Slightly nuclear
condensation at Hep3B. (B) Few nuclear condensations. (C) Slightly nuclear activation at SNU449.
(D) No morphological alteration at SNU449.
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Figure 9. Quantification analysis of nuclear morphology after DAPI staining. (A) Hep3B cells exposed
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r st l i let cell r liferation assay is a colorimetric method based on the use of crystal violet as
basic dye with avidity to nuclear structures. After binding a s l ili ti f t cr st l violet,
tical e sit easurements of extracted dye provide a measure of the relative number of viable cells.
This test has the advantage that it is less time consuming, easier to perf rm and more objective [29].
Encapsulated peptides (P17 and P144) have an antiproliferative influence on human liver cancer
cell li es (SNU449 and Hep3B) s shown by proliferation ass y. Both encapsulated peptides (P17
and P144) inhibited the proliferation of human liver cancer cell lines in vitro in a dose-dependent
manner. This in ibiti n was substantial in both cell lines after treatment, with significant differe ces
from 10 µg/mL to 200 µg/mL in treated cells (Figure 10). Si ilar to our findings, it is reported that P17
and P144 induced antiproliferation effect against human lung cancer cell lines [44] an glioblastoma
cell lines [45,46], respectively. On the other hand, Hep3B and SNU449 cell lines exhibited significant
proliferation after their exposure to free capsules for 72 h.
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3.6. Effects of P144 and P17 on SMAD2 Phosphorylation
SMADs are a group of encoded homologs mammalian protein identified by Small (Sma) and
Mothers against dpp (Mad) genes that act as intracellular transcriptional factors [47]. SMAD2 and
SMAD3 can be phosphorylated by the TGFβRI after the direct binding of TGFβ ligand to its specific
receptors (TGFβRII). This enables them to form heteromeric complexes with SMAD4. This complex is
translocated into the nucleus to regulate target genes [48]. Indeed, we next studied the response to
TGFβ in terms of SMAD2 phosphorylation in both SNU449 and Hep3B cells. SNU449, but not Hep3B,
presented basal SMAD2 phosphorylation. Both cell lines responded to external TGFβ significantly
increasing phosphor-SMAD2 levels (Figure 11). Additionally, in the absence of external TGFβ1,
SNU449 cells presented lower phosphorylation of SMAD2 after their exposure to P17, but not after
their exposure to P144. This phosphorylation was not observed in Hep3B cells after their exposure
to P17. However, slight phosphorylation was shown after their exposure to P144. In the presence
of external TGFβ1, SNU449 cells increased the pSMAD2 signal after their exposure to P17 and P144.
However, Hep3B presented lower phosphorylation of SMAD2 after their exposure to P17, but not after
their exposure to P144. Interestingly, in the absence of the external TGFβ1, the encapsulated P17 and
P144 caused a reduction of SMAD2 phosphorylation in both SNU449 and Hep3B cells. In presence
of the external TGF β1, encapsulated P17 clearly attenuated the level of SMAD2 phosphorylation in
Hep3B cells and both encapsulated P144 and P17 attenuated SMAD2 phosphorylation in SNU449 cells.
These results indicate that the encapsulation of P17 and P144 clearly shows advantages regarding their
biological activity when compared with non-encapsulated peptides, particularly in the mesenchymal,
more invasive, SNU449 cell line.
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4. Discu sion
TGFβ1 inhibitory peptides have a tracted much interest recently because of their ability to block
the TGFβ1 signaling pathway [49], due to their po sible binding to the extrace lular region where the
TGFβ1 ligand connects with its ce lular receptors [30]. It is reported previously that the bulk of P144
can be separated into sma l particles by using sonication [30]. However, these sma l particles tend to
be aggregated. This action may attribute their lo s of the physicochemical interaction after sonication.
Such action leads to the distribution of the electrostatic balance among these particles. For this reason,
the sma l particles tend to be aggregated back after their separation. In the cu rent work, we analyzed
the po sible separation of th se particles by the next interaction with BSA. H nce, these particl s
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are integrated into the moieties of BSA. This coupled interaction drives keeping the small particles
of peptides under electrostatic balance and preventing their aggregation. The demonstration of
rhodamine-labeled peptides exhibited a specific peak at 550 nm which is attributed to the main peak of
pure rhodamine [32]. Increasingly, the second peak was shown at 490 nm, which is similar to the main
peaks of fluorescent isocyanate [50]. Perhaps, the central carbon atom of the chromophore is influenced
by the ionic stress of the complex leading to a shift of both absorption and fluorescence emission related
to the presence of tryptophan [35]. Rhodamine-labeled peptides advanced our knowledge concerning
the physicochemical properties of these two peptides. For instance, their aggregation was localized
even after their cellular uptake around the cytoplasmic region. This evidence was first detected by
using fluorescence microscopy after their precipitation upon the surface of the slide (Figure 1G). In the
same way, small particles of both peptides were compacted after their internalization with no equal
distribution in the perinuclear region. To evaluate their aggregation, ImageJ analysis was used and it
refers to the presence of an aggregation state in non-encapsulated peptides compared to encapsulated
peptides (Supplementary Materials, Figure S1).
The protein–peptide assembly was further functionalized by protamine sulfate. This provides
a novel strategy in terms of α helix titration resulting in turbidity [34]. Arginine rich protamine is
responsible for this turbidity and it perhaps causes modification to the diameter of nanoparticles [51].
Furthermore, there is no published report observing immune-stimulatory side effects related to the
use of protamine [51,52]. To increase their adhesion and cellular adsorption, this complex was further
functionalized by folic acid conjugated carboxymethyl cellulose.
Apart from cellular adsorption, the DAPI staining noticeably revealed nuclear morphological
changes in both SNU449 and Hep3B human liver cancer cell lines in terms of nuclear fragmentation,
nuclear hypotrophy, nuclear condensation and cell structure loss. Accordingly, the present results
proved significantly the potential efficient therapy of both encapsulated peptides against the analyzed
cell lines. Similar to our results, P144 and P17 treatment resulted in significant inhibition at lung cancer
cell lines [44] and the growth of glioblastoma cell lines [46] respectively. When analyzing the effects of
encapsulated versus non-encapsulated peptides at the cellular level, we observed that the efficiency
of the encapsulated peptides was remarkably higher in the SNU449 cells. We and other authors had
previously demonstrated that the SNU449 cells show autocrine stimulation of the TGFβ pathway and
respond to TGF-β increasing Smad2/3 phosphorylation [53]. These cells are resistant to the suppressor
effects of TGFβ [54] and respond to it undergoing EMT. Here, we show that encapsulated peptides
(P17 and P144) induced significant inhibition of basal pSMAD2 in SNU449 cells when compared
to non-encapsulated peptides. Additionally, pSMAD2 phosphorylation is considerably attenuated
after TGFβ treatment. In summary, the transforming growth factor β (TGF-β) signaling pathway
consists of extracellular ligands (including the TGF-β-like group and BMP-like group). The TGF-β-like
group generally phosphorylates SMAD2 and SMAD3, whereas the BMP-like group generally induces
phosphorylation of SMAD1, SMAD5 and SAMD8 [55]. The activated R-SMADs form hetero-oligomeric
complexes with Co-SMAD (SMAD4), which are translocated to the nucleus where they regulate the
expression of target genes. In general, both pathways are translocated into the nucleus to translate
the signal [56]. In this recent study, the phosphorylation of SMAD2 was studied using Western blot
analysis. Additionally, nuclear alteration was distinguished.
5. Conclusions
In conclusion, the encapsulation of TGFβ inhibitory peptides (P17 and P144) has shown potential
therapeutic inhibition to basal phospho-SMAD as a result of TGF-β pathway regulation. It has
proved clearly their ability to inhibit the autocrine TGFβ pathway and basal nuclear SMAD. However,
SNU449 is one of the cell lines that is more responsive to those encapsulated by P17 and P144 is a
mesenchymal, invasive HCC cell line that produces TGFβ autocrinally and is unresponsive to its
suppressor effects. Additionally, rhodamine-labeled peptides enable researchers to follow nearly the
localization of peptides inside cytoplasm after their cellular uptake. In the current studies and our
Pharmaceutics 2020, 12, 421 15 of 18
previous studies indicated that encapsulation of TGFβ signaling pathway inhibitors may facilitate
their delivery and overcome their cytotoxicity. Additionally, folic acid functionalized drug delivery
systems enable them to reach and accumulate inside cancer cells [57–62].
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/5/421/s1,
Figure S1: Fluorescence microscopy images for labelled P144, Scheme S1: (A): Folic Acid conjugated carboxymethyl
cellulose. (B) Labelling carboxymethyl cellulose with FITC, Scheme S2: Fabrication of protein mucoadhesive
targeted therapy.
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